Related references
Note: Only part of the references are listed.In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba
Maria-Teresa Illnait-Zaragozi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species
Jesus Guinea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005:: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus
Peter A. Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Epidemiology of candidemia in Brazil:: a nationwide sentinel surveillance of candidemia in eleven medical Centers
Arnaldo L. Colombo et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers
A Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program
RA Hajjeh et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
